In a groundbreaking study poised to reshape our understanding of neurodegenerative disorders, researchers have unveiled pivotal insights into the prodromal phase of body-first Lewy body disease, a form of Parkinson’s-related pathology. This investigation explores the critical degeneration occurring in the cardiac sympathetic nervous system, illuminating how deviations in autonomic nerve function precede the more widely recognized motor symptoms by years, or even decades. The study, led by Skjærbæk, Munk, Andersen, and colleagues, leverages advanced neuroimaging and molecular techniques to trace the trajectory of sympathetic nerve loss in the heart, providing a novel biomarker for disease onset long before clinical diagnosis becomes possible.
Lewy body diseases, encompassing conditions such as Parkinson’s disease and dementia with Lewy bodies, are characterized by the abnormal accumulation of alpha-synuclein protein in neuronal tissues. Traditionally, clinical diagnosis hinges on overt motor dysfunction, which belies the deep prodromal changes silently unfolding within the autonomic nervous system. This research specifically investigates the degeneration of cardiac sympathetic nerves, a process hypothesized to mark the commencement of the body-first subtype of Lewy body disease. The body-first paradigm suggests pathological alpha-synuclein aggregates initially manifest in peripheral autonomic structures before spreading to central nervous system regions responsible for movement control, reframing our pathological timeline.
Utilizing state-of-the-art positron emission tomography (PET) targeting sympathetic innervation indicators, the authors quantitatively analyze cardiac sympathetic denervation in a cohort comprising individuals across different stages of Lewy body disease progression. Their longitudinal data not only confirm the presence of early and measurable loss of sympathetic nerve terminals in the myocardium but also correlate these changes with subsequent cognitive decline and motor deficit severity. This correlation establishes sympathetic denervation as an integral element of disease staging and progression, which has profound implications for early diagnosis and therapeutic intervention.
A particularly innovative aspect of this study is the employment of novel radiotracers that bind selectively to norepinephrine transporters in peripheral autonomic neurons. These molecular imaging tools allow for unprecedented precision in mapping sympathetic nerve integrity, distinguishing subtle changes inaccessible by traditional diagnostic modalities. By quantifying transporter availability, the research provides a functional map of the cardiac autonomic innervation state, creating an objective metric to monitor disease evolution from a prodromal phase to overt clinical manifestation.
Moreover, data from neuropathological examinations complement the imaging findings, revealing a direct relationship between cardiac sympathetic axonal loss and alpha-synuclein deposition in the peripheral autonomic ganglia. This convergence of in vivo imaging and post-mortem pathology solidifies the concept of cardiac sympathetic denervation as a hallmark of early Lewy body disease. It also challenges the neurocentric dogma by highlighting the significance of peripheral nervous system involvement in neurodegeneration, a perspective that could revolutionize biomarker development and therapeutic targeting.
The timeline delineated in this study indicates that cardiac sympathetic degeneration precedes not only motor symptoms but also other autonomic symptoms such as constipation or orthostatic hypotension, marking an even earlier window for intervention. Understanding this prodromal duration is vital for designing clinical trials aiming to halt or slow the progression of Lewy body disease. Early detection via cardiac sympathetic imaging could enable patient stratification at a stage when neuroprotective therapies might be most effective, potentially altering the disease course.
Importantly, this research differentiates between body-first and brain-first subtypes of Lewy body pathology, a distinction with significant pathophysiological and therapeutic ramifications. The body-first subtype begins in peripheral autonomic nervous structures, while the brain-first subtype initiates within the central nervous system. The observed cardiac sympathetic degeneration exclusively delineates the timeline for the body-first variant, suggesting subtype-specific biomarkers and tailored clinical approaches. This nuanced understanding could explain why patients present with variable autonomic symptoms and progression rates, thus personalizing medical management strategies.
The authors propose that sympathetic nerve loss in the heart impacts cardiac function subtly but progressively, contributing to autonomic dysfunction symptoms commonly reported in Lewy body disease. The implications extend beyond diagnosis into symptom management, as cardiac autonomic impairment can predispose patients to arrhythmias and other cardiovascular complications. By identifying this degeneration early, clinicians might mitigate these risks with cardioselective interventions, enhancing quality of life beyond standard neurological care.
From a mechanistic viewpoint, the study highlights the toxic role of misfolded alpha-synuclein aggregates in triggering axonal degeneration and disrupting neurochemical signaling in peripheral autonomic nerves. This neuropathology underpins the loss of cardiac sympathetic tone observed through imaging. The findings suggest potential therapeutic avenues targeting alpha-synuclein pathology in the peripheral nervous system, a relatively unexplored terrain compared to central nervous system interventions. Such peripheral-targeted therapies could arrest or reverse early disease changes before central nervous involvement complicates treatment.
This investigation also challenges existing paradigms about neurodegeneration’s anatomical origins, urging a broader conception that integrates peripheral autonomic nervous system vulnerability with central neurodegeneration. The holistic perspective fosters interdisciplinary research bridging cardiology, neurology, and molecular imaging, thereby expanding the toolkit available to combat Lewy body diseases. It prompts reevaluation of diagnostic criteria and suggests incorporating peripheral autonomic assessments as standard practice in suspected Lewy body cases.
In clinical settings, this cardiac-centric biomarker may revolutionize screening for at-risk populations, such as individuals with prodromal autonomic complaints or genetic predispositions. Earlier diagnosis based on sympathetic denervation could allow timely counseling and initiation of neuroprotective lifestyle changes and pharmacological therapies. Such early intervention strategies are essential in diseases like Lewy body pathology, where neuronal loss in the brain is currently irreversible and symptom management remains palliative.
Furthermore, the study’s forensic implications extend to more accurate disease staging in post-mortem brain banking and research. The presence and extent of cardiac sympathetic loss could serve as an additional pathological criterion to classify Lewy body disease subtypes, enhancing the precision of neuropathological diagnoses. This granularity in classification could augment clinical trial recruitment by ensuring homogeneous patient populations, thereby increasing trial efficacy and reproducibility of results.
The authors acknowledge limitations such as the current availability and cost of advanced PET radiotracers, which may restrict widespread clinical adoption in the short term. They advocate for ongoing research to develop more accessible and non-invasive biomarkers, including skin biopsies and wearable autonomic function monitors. However, the current study sets a benchmark, demonstrating the feasibility and critical importance of targeting cardiac sympathetic degeneration in Lewy body disease research and clinical care.
Overall, this research delivers an unprecedented window into the earliest phases of body-first Lewy body disease by spotlighting cardiac sympathetic nerve loss as both a marker and mechanistic player in disease pathogenesis. The evidence amassed compellingly argues for a paradigm shift toward recognizing peripheral autonomic nervous system involvement as a foundational element of Lewy body pathology progression. This shift could usher in an era of early detection and intervention, transforming patient outcomes from late-stage palliation to proactive disease modulation.
Looking forward, the clinical translation of these findings may culminate in routine cardiac sympathetic imaging as part of neurodegenerative disease diagnostics, coupled with integrated therapeutic strategies targeting peripheral autonomic pathology. This holistic approach offers hope of fundamentally altering the natural history of Lewy body disease by halting pathological progression before irreversible central nervous system damage ensues. As such, the study by Skjærbæk and colleagues not only challenges existing scientific dogma but also lights the way toward a new frontier in neurodegenerative disease management and research.
Subject of Research: Cardiac sympathetic degeneration as a biomarker and mechanistic insight into the prodromal phase of body-first Lewy body disease.
Article Title: Cardiac sympathetic degeneration informs the duration of the prodromal stage of body-first Lewy body disease.
Article References:
Skjærbæk, C., Munk, O.L., Andersen, K.B. et al. Cardiac sympathetic degeneration informs the duration of the prodromal stage of body-first Lewy body disease. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01455-z
Image Credits: AI Generated
Tags: alpha-synuclein pathology progressionautonomic nervous system dysfunctionbody-first Lewy body diseasecardiac sympathetic nerve degenerationdementia with Lewy bodies pathologyearly detection of Lewy body disordersmolecular biomarkers for Parkinson’sneuroimaging in Lewy body diseaseParkinson’s disease non-motor symptomsperipheral autonomic nervous system involvementprodromal phase of Parkinson’ssympathetic nervous system and neurodegeneration
